Analyst firms · Leerink Partners · PFE

Leerink Partners PFE price target and rating history

Pfizer Inc. (PFE) · Health Care

Leerink Partners rates Pfizer Inc. (PFE) Mkt Perform with a $55 price target, as of its latest action on May 23, 2022. It has published 5 rating actions on PFE since July 2021, including 0 upgrades and 0 downgrades. Across 7 firms with a PFE price target in the last 12 months, the median target is $26.

Current rating
Mkt Perform
Price target
$55
Median target, all firms
$26
Actions on PFE
5

Leerink Partners price target on PFE

$56$52$4820222023202420252026
Leerink Partners price target on PFE, each point a stated target, July 2021 to May 2022.

Every Leerink Partners rating on PFE

How other firms rate PFE

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
DZ BankHoldNov 6, 2026
HSBCHold$28Jul 6, 2026
RBC Capital MarketsSector Perform$25Jun 10, 2026
Argus ResearchBuy$35Mar 2, 2026
BarclaysUnderweight$25Feb 20, 2026
DaiwaNeutral$27Feb 12, 2026
UBSNeutral$25Jan 7, 2026
CitigroupNeutral$26Dec 2, 2025

Questions about Leerink Partners and PFE

What is Leerink Partners's price target for PFE?
Leerink Partners's latest stated price target for Pfizer Inc. (PFE) is $55, from its action on May 23, 2022.
What is Leerink Partners's rating on PFE?
Leerink Partners rates PFE Mkt Perform, a neutral rating, as of May 23, 2022.
When did Leerink Partners last change its view on PFE?
On May 23, 2022, Leerink Partners starts coverage at Mkt Perform, price target $55.
How does Leerink Partners's PFE target compare with other analysts?
Across 7 firms with a PFE price target in the last 12 months, the median target is $26.

More PFE rating histories

All Leerink Partners ratingsPFE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.